Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an ...

Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 First Quarter Conference Call. My name is Clint ...

Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...

This work presents potentially important findings suggesting that a combination of transcranial stimulation approaches applied for a short period could improve memory performance after administration.

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

We sat down with Pro Medicus CEO, Dr Sam Hupert on results day to discuss the past six months and the all-important outlook.